Please login to the form below

FALCON trial of fulvestrant for advanced breast cancer

The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer.


Summary/transcript

Prof. Matthew Ellis from the Baylor College of Medicine presented the trial and talked to us about its design, the results and implications. In the interview, he explains that the study was designed to address the question if there is an optimal first-line endocrine therapy for patients with hormone receptor-positive advanced breast cancer who had not been treated with a hormonal agent before.

The primary endpoint of the study was progression-free survival (PFS); Prof. Ellis highlights that “patients on fulvestrant stayed on the drug in response approximately three months longer than patients on anastrozole” (16.6 months vs 13.8 months).

Prof. Ellis further points out that the results were statistically significant but the question is, if they are clinically significant. He explains that these kinds of differences as observed in this trial, have driven changes in clinical practice before as in the case of tamoxifen and aromatase inhibitors.

If you would like to discover how we can leverage our network of relationships and understanding of the oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact either Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.

17th November 2016

Share

Tags

Company Details

Brandcast Health

+44 (0)20 7291 5070

Contact Website

Address:
16-17 Little Portland Street
London
W1W 8BP

Latest content on this profile

Ansar Jawair discusses precision medicines - what they are, where we are today and their future
Ansar Jawair, Founder and CEO of Precision Medicines Ltd, tells us about his talk on precision medicines, what they are, where we are today, the future and some of the challenges involved in their implementation to patients. Precision medicines are matched to patients using biomarkers, enabling to target the specific drivers of various cancers. Major advances have already been made in this field, treating a range of cancers. Some of the major challenges include working with the complexities in different countries, trying to establish diagnostic testing, for enabling precision medicine. He mentions how we are moving towards an era of delivering personalised treatments that are matched to the individual patient. Furthermore, through advances in precision medicines and in diagnostic testing, we are seeing earlier detection of disease and identification of risk factors, allowing for preventative measures.
Brandcast Health
Oradit Ido talks about the Unique Israeli Entrepreneurial Ecosystem
Orado provides an overview of why she believes Israel is unique in its approach to innovation. With a history of overcoming challenges, a people who pride themselves on their chutzpe (audaciousness), and a fast paced culture, she explains why she thinks Israel provides a perfect ecosystem for innovation and entrepreneurship. She explains that within medicine and healthcare, there is a need for strategic support and engagement, and as an example of how the government is supporting this she provides an overview of the Ministry of Health challenge tender programme.
Brandcast Health
Acute leukaemia patients get new online information centre that will help them get the best possible care
A unique collaboration between some of the world's leading leukaemia experts and the patient community in the UK and across Europe has resulted in the development of a one-of-a-kind educational resource centre that provides acute leukaemia patients with the support they need, when they need it most. It is the first time that such a comprehensive medical information video resource has been gathered together in this format and comes at a time when cancer patients and caregivers are advocating for a bigger say in decisions about their individual treatment regimens.
Brandcast Health
Aubrey De Grey provides a summary of his goal of combating ageing
Aubrey believes ageing is a serious issue, not only because people die of old age, but because it causes suffering. He discusses the fact that many diseases including chronic cancer, are the result of ageing and that by tackling ageing of cells, we can address many of the issues associated with poor health. To find out more about Aubrey and the SENS Research Foundation visit: http://www.sens.org/
Brandcast Health
Oradit Ido talks about the Unique Israeli Entrepreneurial Ecosystem
Orado provides an overview of why she believes Israel is unique in its approach to innovation. With a history of overcoming challenges, a people who pride themselves on their chutzpe (audaciousness), and a fast paced culture, she explains why she thinks Israel provides a perfect ecosystem for innovation and entrepreneurship. She explains that within medicine and healthcare, there is a need for strategic support and engagement, and as an example of how the government is supporting this she provides an overview of the Ministry of Health challenge tender programme.
Brandcast Health
HaemOncCam #Haem2016

Brandcast Health